BGM1812 vs petrelintide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: Amylin/calcitonin receptor (dual) · full Obesity pipeline

BGM1812

Developed by BrightGene Bio-Medical Technology

Phase 2 in Obesitypeptide
Weak signal

NCT07224399 · Phase 1 · completed

A randomised, double-blind, placebo-controlled single- and multiple-ascending-dose Phase 1 study in 60 participants with BMI 28.6 to 36.2. Its primary endpoint is safety and tolerability, with weight loss only a secondary endpoint, so it is not efficacy evidence. The sponsor reports no serious adverse events and placebo-adjusted weight loss of 0.2% to 9.2%.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: August 2027 · NCT07918625 (registry estimate)

Reported efficacy

Number of treatment adverse events (Predose up to 6 weeks (Part A) & 9 weeks (Part B)): Placebo-adjusted weight loss 0.2% to 9.2% (LS mean) across dose groups (0.3 to 7.2 mg once weekly for 1 to 4 weeks); no serious adverse events (sponsor-reported, 7 August 2026) (not_applicable)

Result source: NCT07224399

petrelintide

Developed by Zealand Pharma and partners

Phase 3 in Obesitypeptide
Partial signal

NCT06662539 · Phase 2 · completed

The study was randomized and double-blind, used matching placebo, and enrolled 493 participants. Its primary clinical endpoint was change in body weight, but the outcome comparison is not yet available because results have not been posted.

Next expected readout: November 2027 · NCT07589686 (registry estimate)

Reported efficacy

Percent change from baseline in body weight to Week 28 (From Baseline (Day 1) to Week 28): Primary endpoint met: statistically significant weight reduction vs placebo at week 28 in all five dose arms; up to 10.7% mean reduction at week 42 vs 1.7% with placebo (ZUPREME-1, 2026-03-05). (met)

Result source: NCT06662539

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBGM1812petrelintide
Body weight, % change—Not reported—Trial running · NCT07843485
Weight loss of 5% or more—Not reported—Trial running · NCT07843485
Weight loss of 10% or more—Not reported—Trial running · NCT07843485
Waist circumference, change (cm)—Not reported—Trial running · NCT07843485

Body weight, % change

BGM1812
—Not reported
petrelintide
—Trial running · NCT07843485

Weight loss of 5% or more

BGM1812
—Not reported
petrelintide
—Trial running · NCT07843485

Weight loss of 10% or more

BGM1812
—Not reported
petrelintide
—Trial running · NCT07843485

Waist circumference, change (cm)

BGM1812
—Not reported
petrelintide
—Trial running · NCT07843485
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

BGM1812
Placebo-adjusted weight loss 0.2% to 9.2% (LS mean) across dose groups (0.3 to 7.2 mg once weekly for 1 to 4 weeks); no serious adverse events (sponsor-reported, 7 August 2026) NCT07224399 · Phase 1 · design grade: weak · reviewed ClinicalTrials.gov result
petrelintide
Primary endpoint met: statistically significant weight reduction vs placebo at week 28 in all five dose arms; up to 10.7% mean reduction at week 42 vs 1.7% with placebo (ZUPREME-1, 2026-03-05). NCT06662539 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BGM1812's landscape · petrelintide's landscape